Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R21 Clinical Trial Not Allowed)
This funding opportunity is designed to support researchers exploring how RNA modifications affect brain aging and contribute to Alzheimer's disease and related dementias.
The purpose of this Notice of Funding Opportunity (NOFO) is to catalyze innovative research to elucidate the molecular landscape and functional implications of RNA modifications in brain aging and Alzheimer's disease (AD) and AD-related dementias (ADRD). AD-related dementias include Lewy body dementia (LBD), frontotemporal dementia (FTD), vascular cognitive impairment/dementia (VCI/D), and mixed dementias.This NOFO supports exploratory and developmental grant (R21) applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis of AD/ADRD. Proposed studies should focus on functional characterization and mechanistic investigation of previously identified RNA modifications.
Award Range
Not specified - $275,000
Total Program Funding
$1,400,000
Number of Awards
5
Matching Requirement
No
Eligible Applicants
Additional Requirements
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Geographic Eligibility
All
Application Opens
July 31, 2024
Application Closes
November 1, 2024
Grantor
U.S. Department of Health and Human Services (National Institutes of Health)
Subscribe to view contact details